ESTRO 2024 - Abstract Book

S676

Clinical - Breast

ESTRO 2024

pT1

516

464

822

606

(N=2.408)

(82.6)

(46.7)

(69.4)

(25.2)

pT2/pT3

103

522

357

589

(N=1.571)

(16.5)

(52.5)

(30.1)

(49.1)

Missing

6

6

6

5

(N=25)

(1.0)

(0.8)

(0.5)

(0.4)

Pathological N stage

<.0001

pN0

600

257

701

220

(N=1.778)

(96.0)

(25.9)

(59.2)

(18.3)

pN1

19

530

426

750

(N=1.725)

(3.0)

(53.3)

(36.0)

(62.5)

pN2/N3

4

207

58

230

(N=499) Missing

(0.6)

(20.8)

(4.9)

(19.2)

2

0

0

0

(N=2)

(0.3)

(0.0)

(0.0)

(0.0)

Tumour stage

<.0001

Stage I

502

150

575

117

(N=1.344)

(80.3)

(15.1)

(48.5)

(9.8)

Stage IIa

106

339

346

504

(N=1.295)

(17.0)

(34.1)

(29.2)

(42.0)

Stage IIb

8

273

187

309

(N=777) Stage III

(1.3)

(27.5)

(15.8)

(25.8)

3

225

71

265

(N=564) Missing

(0.5)

(22.6)

(6.0)

(22.1)

6

7

6

5

(N=24)

(1.0)

(0.7)

(0.5)

(0.4)

Combination

of

ER/PG

<.0001

status

ER+,PR+

341

230

804

805

(N=2.180)

(54.6)

(23.1)

(67.9)

(67.1)

ER+,PR- ,unknown (N=764)

88

85

287

304

(14.1)

(8.6)

(24.2)

(25.3)

PG+,ER-,unknown

29

56

19

53